ADCT Stock: ADC Therapeutics S.A. Stock Price, Analysis & Insights
Get live adct stock price $3.06, comprehensive ADC Therapeutics S.A. stock analysis, charts, news, and expert forecast. Real-time adct stock data and investment insights.
Loading chart...
Company Overview
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Company Information
- CEO
- Ameet Mallik
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 263
Contact Information
- Address
- Biopole
- Country
- CH
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Higher growth potential with elevated volatility (Beta: 1.89)
Business Model & Strategy
ADC Therapeutics S.A. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Ameet Mallik, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
ADC Therapeutics S.A. competes in the Biotechnology within the broader Healthcare. With 353.5 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the New York Stock Exchange, ADC Therapeutics S.A. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating ADC Therapeutics S.A. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for ADC Therapeutics S.A. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for ADC Therapeutics S.A.
- ⚠Investors should consider how ADC Therapeutics S.A. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
353.48M
P/E Ratio
-2.17
Beta
1.89
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 353.48M market capitalization
- Trading Volume: 5.65M shares traded today
- Price Range: 52-week range of $1.05 - $4.80
- Exchange: Listed on New York Stock Exchange
Financial Metrics
Market Analysis for ADC Therapeutics S.A.
ADC Therapeutics S.A. (ADCT) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 353.48M, the company represents a significant player in its market. The stock is currently trading at $3.06 with a negativedaily change of 33.59%.
The company's 263 employee base and presence on the New York Stock Exchangeexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -2.17, beta of 1.89, and 52-week price range from $1.05 to $4.80when evaluating investment opportunities.
Why Invest in ADC Therapeutics S.A.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (New York Stock Exchange)
- • Experienced leadership under Ameet Mallik
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.